Swiss pharmaceutical giant Roche agreed to buy US company 89bio, specialized in the development of medications for liver diseases and cardiometabolic disorders. The value of the transaction is about $ 3.5 billion, including a basic price of $ 14.50 per share and an additional possible payment of up to $ 6 per share, depending on the business results.
The offer is 79 percent higher than yesterday’s market price of the shares 89bio, and the completion of acquisition is expected by the end of the year. After joining, employees 89bio will become part of the Roche’s pharmaceutical department.
89Bio develops the medicine Pegozafermin for non-alcoholic fatty liver disease (MASH), which affects 5 to 7 percent of the world’s population and can cause severe complications such as cirrhosis and liver cancer.
Rochea Thomas Schinker points out that this acquisition will strengthen their portfolio of drugs for cardiovascular and metabolic diseases, while 89bi’s entire Rohan Parker believes that the partnership will accelerate the development and bring more benefit to patients.
(Vijesti.ba)
